Overview

Relative Bioavailability of ESK-001 Tablet Versus Liquid in Healthy Participants

Status:
Recruiting
Trial end date:
2022-04-01
Target enrollment:
Participant gender:
Summary
This is a single-center, in-house, open-label, crossover study in 15 healthy participants.
Phase:
Phase 1
Details
Lead Sponsor:
Alumis Inc
Treatments:
Rabeprazole